The articaine hydrochloride market is expected to reach USD 1383.34 Million by 2030 at 8.10% CAGR during the forecast period 2022-2030.
Articaine is a form of a local amide anesthetic that is most commonly used in dentistry. The articaine is marketed as a colorless liquid in vials/cartridges (2ml in each vial/cartridge). It is available in two variants, i.e., Articaine-100 & Articaine-200. Articaine-200 is more potent than Articaine-100. The dosage can be based on the type and extent of surgical procedure, depth of anesthesia, degree of muscular relaxation, and condition of the patient. For pediatric patients, dosage based on their age, weight, the physical condition of the patient, and the extent of the surgical procedure.
The articaine hydrochloride industry is growing rapidly. Articaine, with its greater ability to diffuse through tissues, become a very widely used local anesthetic in the European and Canadian markets.
Articaine hydrochloride is the most popular local anesthetic for dentistry. For example, in Germany, around 97% of the anesthetic used by dentists is articaine hydrochloride. The growth of the market is likely to be driven by increasing incidences of dental caries and other periodontal diseases, advancement in dental anesthesia delivery system device, increasing the use of articaine for dental surgery, innovative nature of the dental anesthetics industry, and vigorous research and development efforts. Periodontal disease is one of the major dental diseases that influence human populations worldwide at high prevalence rates. Periodontal diseases are more prevalent in Asia-Pacific. Lack of the most basic oral health education and limited availability of simple interventions like pain relief and emergency care for acute infection and trauma to the vast majority of the population, especially in the rural areas are major reasons for the high incidences of periodontal diseases in the region. According to the FDI World Dental Federation, more than 80% of people in Asia-Pacific, including countries such as India, Bangladesh, Nepal, Malaysia, and Indonesia, suffer from dental decay. Furthermore, 40–59% of the population in China and Australia suffer from dental caries.
Some of the popular local anesthesia other than articaine are prilocaine, lidocaine, mepivacaine, and bupivacaine. The availability and usage of alternative products are likely to thwart the growth of the articaine hydrochloride market during the forecast period.
Articaine Hydrochloride Market Size, by End User, 2018 and 2025 (USD Million) Source: MRFR Analysis
The articaine hydrochloride market has been segmented into application and end user. Based on application, the global market has been segmented into infiltration, nerve block, and others. Based on end-user, the global market has been segmented into dental clinics, hospitals, and academics & research institutes. The dental clinics segment accounted for a market value of USD 798.5 million in 2018.
The prominent players in the articaine hydrochloride market are 3M (US), Anhui BBCA Pharmaceutical Co., Ltd. (China), Dentsply Sirona (US), Inibsa Dental S.L.U (Spain), Jinan Chenghui Shuangda Chemical Co., Ltd. (China), Jinan Ruixing Pharmaceutical Technology Co., Ltd (China), Manus Aktteva Biopharma LLP (India), Pfizer Inc. (US), Pierrel S.p.A (Italy), Sanofi (France), Septodont (France), Siegfried AG (Switzerland), and Sigma Aldrich (US).
Some of the key strategies followed by the players operating in the articaine hydrochloride market were innovation, product development, acquisition, and expansion.
Asia-Pacific Articaine Hydrochloride Market Share, by Country, 2018 (%)
Source: MRFR Analysis
The articaine hydrochloride market, based on region, is segmented into Europe, North America, Asia-Pacific, and the Middle East and Africa. The articaine hydrochloride market in Europe is the largest region in the market and is expected to develop continuously due to the increasing demand and focus on dental treatments. The growing awareness of preventative and corrective treatment in European countries is also one of the factors driving the growth of this market. The articaine hydrochloride market in Europe is mainly focusing on a new style of management system that would engage dental specialists to run more effective practices and permit them to concentrate on better clinical care.
North America accounted for the second-largest share in the articaine hydrochloride market. The increasing acceptance of the articaine by dental professionals is one of the factors for the growth of the articaine hydrochloride market in this region.
Asia-Pacific is one of the fastest-growing markets for articaine hydrochloride. Although Australia is dominating the Asia-Pacific market with high adoption of new technology and its usage of dental applications, China, Japan, and India are the countries mainly responsible for the exponential growth of the articaine hydrochloride market in Asia-Pacific. The demand for articaine hydrochloride in India offers several growth opportunities owing to the rising awareness of new applications. In Asia-Pacific, India accounted for a market share of 8.5% in 2018.
Articaine Hydrochloride Market, by Application
Articaine Hydrochloride Market, by End User
Articaine Hydrochloride Market, by Region
Available Additional Customizations
|Market Size||USD 1383.34 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Application, End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||3M (US), Anhui BBCA Pharmaceutical Co., Ltd. (China), Dentsply Sirona (US), Inibsa Dental S.L.U (Spain), Jinan Chenghui Shuangda Chemical Co., Ltd. (China), Jinan Ruixing Pharmaceutical Technology Co., Ltd (China), Manus Aktteva Biopharma LLP (India), Pfizer Inc. (US), Pierrel S.p.A (Italy), Sanofi (France), Septodont (France), Siegfried AG (Switzerland), and Sigma Aldrich (US).|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||
The projected CAGR would be 8.10% during the forecast period (2022-2030).
The projected valuation would be USD 1383.34 Million.
The dental clinic segment is leading the market.
The European articaine hydrochloride market has the maximum market share.
The Asia Pacific articaine hydrochloride market would be the fastest-growing market.